Disabling Cellular Recycling Gene Boosts Hard-to-Make Drug Protein Yields
Researchers in November 2026 disabled cellular recycling systems in a human cell line to significantly increase the manufacturing yields of difficult target proteins used in medicine development, according to a study published in Cell Systems.
Key Clinical Takeaways:
- Disabling the cellular recycling pathway, specifically by removing the ULK1 gene, increased yields of three difficult target proteins without harming host cell health.
- Production of the model proteins GIPR, GPR75, and P2X3 increased by 30 percent, 80 percent, and 100 percent, respectively, in the modified human cell line.
- The international research collaboration between the KTH Royal Institute of Technology and AstraZeneca points to autophagy as a new target for host cell engineering in pharmaceutical manufacturing.
Membrane proteins serve as the biological targets for approximately 60 percent of all approved medicines. Despite their critical role in pharmacology, these specific proteins remain notoriously difficult to manufacture in quantities large enough for effective research and development, creating a persistent bottleneck in the pharmaceutical industry.
Addressing this manufacturing hurdle, a team at the KTH Royal Institute of Technology worked in collaboration with AstraZeneca to test an unconventional approach to cell engineering. Rather than attempting to strengthen the protein production machinery inside cells, the researchers disrupted the cellular clean-up crew responsible for breaking down and recycling proteins and organelles.
The team specifically knocked out the gene known as ULK1, which initiates the process of autophagy. While autophagy is widely considered essential for normal cell health and vitality, removing the gene caused no observed damage to the human cell line used in the experiment.

“We expected cells without working autophagy to struggle,” said Johan Rockberg, professor of directed evolution at the KTH Royal Institute of Technology, as reported by News-Medical. “Instead, they produced more, and they did best with exactly the proteins that are usually hardest to obtain.”
Evaluating Protein Yield Outcomes
| Target Protein | Yield Increase | Primary Outlet |
|---|---|---|
| GIPR | 30 percent | News-Medical |
| GPR75 | 80 percent | News-Medical |
| P2X3 | 100 percent | News-Medical |
To investigate how the cells managed without this central cellular mechanism, Alice Karlsson, a doctoral student in biotechnology at the KTH Royal Institute of Technology, analyzed internal cellular activity. The analysis revealed clear signs in the transcriptome showing the downregulation of autophagy and subsequent downstream processes.
“The most rewarding part was seeing the effect of knocking out ULK1 and that it led to clear signs in the transcriptome with downregulation of autophagy and downstream processes,” Karlsson said, according to phys.org. “The biggest surprise was that it also translated into higher yields of our model proteins.”
Financial support for the research was provided by the Knut and Alice Wallenberg Foundation, AstraZeneca, and the Swedish innovation agency Vinnova through GeneNova, AAVNova, CellNova, and AdBIOPRO. The findings suggest that targeting autophagy could become a standard strategy in host cell engineering alongside traditional methods of boosting secretory pathways.
Beyond pharmaceutical manufacturing applications, the observed shifts in cellular metabolism and protein turnover may offer relevant insights for studying neurodegenerative conditions. Such disorders are frequently characterized by harmful protein aggregation and impaired cellular clearance mechanisms.
“ULK1 knockout increases recombinant transcript abundance and improves recombinant membrane protein expression,” Karlsson et al. wrote in Cell Systems.
KTH Royal Institute of Technology traces its origins to the Laboratorium Mechanicum, founded in 1697 by Christopher Polhem, and was formally established as the Teknologiska institutet in 1827. It received its current name in 1877 and is now Sweden’s largest technical university, comprising five schools across four campuses in and around Stockholm.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.